- ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
- ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
- ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
- ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
- ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
- ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
- ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
- ProMIS Neurosciences Issues Letter to Shareholders
- ProMIS Neurosciences, Inc. Announces Leadership Transition
- ProMIS Neurosciences Announces Publication on Novel Target for ALS
More ▼
Key statistics
On Friday, ProMIS Neurosciences Inc (PMN:NAQ) closed at 1.96, 106.32% above the 52 week low of 0.95 set on Dec 26, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.05 |
---|---|
High | 2.05 |
Low | 1.90 |
Bid | 0.95 |
Offer | 2.33 |
Previous close | 1.99 |
Average volume | 6.07k |
---|---|
Shares outstanding | 18.96m |
Free float | 14.34m |
P/E (TTM) | -- |
Market cap | 37.16m USD |
EPS (TTM) | -1.22 USD |
Data delayed at least 15 minutes, as of May 03 2024 18:47 BST.
More ▼